Melanotan 1: How It Works, Tanning Results, Dosage, and Side Effects

A clear look at the synthetic alpha-MSH analog used to stimulate melanin production, and what the research actually shows.

Melanotan 1 sits in an unusual category. It is a lab-made peptide that copies a hormone the body already produces. Yet it remains unapproved for cosmetic use in most countries.

The interest around it comes from one observation. It can darken skin without sun exposure.

Understanding the trade-offs requires moving past marketing claims and into the basic biology.

What Melanotan 1 Actually Is

Melanotan 1 is known in pharmaceutical contexts as afamelanotide. It is a synthetic analog of alpha-melanocyte-stimulating hormone, or alpha-MSH.

Alpha-MSH is a peptide hormone produced in the pituitary gland and within the skin. Its main job is to regulate melanin synthesis. That process shapes:

• Skin tone
• Hair color
• Pigment shifts in response to sunlight

The synthetic version was developed at the University of Arizona in the 1980s. Researchers changed the native alpha-MSH sequence to make it more stable. Natural alpha-MSH breaks down quickly in the body, so the modified peptide stays active longer.

Melanotan 1 should not be confused with Melanotan 2. The two peptides have different structures and different effects.

How Melanotan 1 Works

The mechanism centers on melanocortin 1 receptors, or MC1R. These sit on the surface of melanocytes, the skin cells that produce pigment.

When alpha-MSH binds to MC1R, it triggers a signal inside the cell. That signal shifts melanocyte activity toward producing eumelanin, the darker form of melanin that gives skin its bronzed tone in the sun.

Melanotan 1 binds the same receptors. The process that follows looks like this:

• Melanocytes increase eumelanin output
• Pigment transfers to surrounding skin cells called keratinocytes
• Skin gradually darkens, with no UV needed

This is the same pathway the body uses when it tans naturally. The difference is that Melanotan 1 starts the process through a peptide signal rather than through UV-induced skin damage.

Reported Tanning Results

In published research and user reports, pigmentation usually develops over several days to a few weeks. The shift is gradual rather than sudden.

The resulting color tends to be more even than a natural tan. The whole skin surface responds, not just sun-exposed areas.

Individual response varies. Key factors include:

• Baseline MC1R activity. People who tan easily in the sun often respond more readily.
• Genetic variants. Many individuals with red hair and very fair skin carry MC1R variants that respond poorly to alpha-MSH signaling. Their results may be limited.
• Skin cell turnover. Pigmentation fades once the peptide is stopped, as melanocyte activity returns to baseline and pigmented cells are shed.

Dosage Context

Dosage information for cosmetic use comes mostly from online communities, not clinical guidelines. The peptide is not approved for tanning.

The only approved medical use of afamelanotide is for erythropoietic protoporphyria, a rare light-sensitivity disorder. That version is a controlled subcutaneous implant given by a physician.

Cosmetic use happens outside medical supervision. Dosing practices vary widely and have not been validated in controlled studies. This is one of the central concerns regulators raise. Unsupervised injection of an unregulated peptide carries risks that careful dosing alone cannot fully address.

Researching peptides outside of approval pathways?

Unsupervised use is where most peptide problems start — wrong reconstitution, wrong dosing, wrong source. Project Biohacking coaching walks you through sourcing, safety, and protocol decisions before you inject anything.

Explore Peptide Coaching →

Side Effects and Safety Considerations

Reported short-term side effects include:

• Nausea
• Facial flushing
• Reduced appetite
• Fatigue after injection

These tend to be brief.

The more serious concerns involve the skin itself. Reported issues include:

• Mole changes. Existing moles may darken during use.
• New pigmented lesions. Some users develop new spots that were not present before.
• Monitoring complications. Changes in moles can sometimes signal melanoma, which makes dermatology screening harder to interpret.

Case reports in the medical literature describe melanoma diagnoses in Melanotan users. A direct causal link has not been established, and this population is hard to study in a systematic way.

There are also product quality concerns. Peptides sold outside pharmaceutical channels can vary in:

• Purity
• Sterility
• Actual peptide content

Contamination and mislabeling are recurring issues in the gray market for research peptides.

Melanotan 1 is not approved by the FDA, the EMA, or most other regulatory bodies for cosmetic use. Several countries have taken enforcement action against suppliers.

Where the Research Stands

Legitimate clinical research on afamelanotide focuses on conditions where increased melanin offers a clear benefit. These include:

• Erythropoietic protoporphyria
• Certain forms of vitiligo

In those settings, the peptide is given under medical supervision with set protocols.

For tanning purposes, the research base is much thinner. The basic mechanism is well understood. Long-term safety in healthy users seeking cosmetic pigmentation has not been studied with the rigor that normally supports approval.

That gap is the central reason regulators continue to advise against cosmetic use.

Get peptide research that doesn't waste your time

Weekly briefings on what the actual research shows, which vendors pass our testing checks, and what regulators are doing. No hype. No supplement-store nonsense.

Join the Newsletter →

Melanotan 1 FAQ